Hsp90 inhibitors and drug resistance in cancer: The potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs

Biochemical Pharmacology

Volumn 83, Issue 8, 2012, Pages 995-1004

  Lu, Xiangyi ^a   Xiao, Li ^b   Wang, Luan ^a,c   Ruden, Douglas M ^a,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Drug resistance; Geldanamycin; Hsp90

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BORTEZOMIB; CISPLATIN; CYTARABINE; DOXORUBICIN; EMUNIN; GEMCITABINE; GTP 14564; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; IMATINIB; LY 29400; OXALIPLATIN; PACLITAXEL; RADICICOL; RAPAMYCIN; TANESPIMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; KARNOFSKY PERFORMANCE STATUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOQUINONES; BREAST NEOPLASMS; CISPLATIN; COMBINED MODALITY THERAPY; CYSTEINE PROTEINASE INHIBITORS; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; TAXOIDS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84858008290     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.11.011     Document Type: Review

References (188)

1. Echeverria PC, Forafonov F, Pandey DP, Muhlebach G, Picard D. Detection of changes in gene regulatory patterns, elicited by perturbations of the Hsp90 molecular chaperone complex, by visualizing multiple experiments with an animation. BioData Min 2011;4:15.
2. Augello MA, Hickey TE, Knudsen KE. FOXA1: master of steroid receptor function in cancer. EMBO J 2011;30:3885-94.
3. Wayne N, Mishra P, Bolon DN. Hsp90 and client protein maturation. Methods Mol Biol 2011;787:33-44.
4. Memarzadeh S, Cai H, Janzen DM, Xin L, Lukacs R, Riedinger M, et al. Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal. Proc Natl Acad Sci USA 2011;108:7962-7.
5. Imamura T. Epigenetic setting for long-term expression of estrogen receptor alpha and androgen receptor in cells. Horm Behav 2011;59:345-52.
6. Biggar PH, Liangos O, Fey H, Brandenburg VM, Ketteler M. Vitamin D, chronic kidney disease and survival: a pluripotent hormone or just another bone drug. Pediatr Nephrol 2011;26:7-18.
7. Lee JH, Choi KJ, Seo WD, Jang SY, Kim M, Lee BW, et al. Enhancement of radiation sensitivity in lung cancer cells by celastrol is mediated by inhibition of Hsp90. Int J Mol Med 2011;27:441-6.
8. Walsh N, Larkin A, Swan N, Conlon K, Dowling P, McDermott R, et al. RNAi knockdown of Hop (Hsp70/Hsp90 organising protein) decreases invasion via MMP-2 down regulation. Cancer Lett 2011;306:180-9.
9. Ou WB, Hubert C, Corson JM, Bueno R, Flynn DL, Sugarbaker DJ, et al. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma. Neoplasia 2011;13:12-22.
10. Cercek A, Saltz LBEYOND KRAS. Other markers and potential treatment strategies for KRAS mutant and wild-type patients. Curr Treat Opt Oncol 2011;12:126-35.
11. Bai L, Xu S, Chen W, Li Z, Wang X, Tang H, et al. Blocking NF-kappaB and Akt by Hsp90 inhibition sensitizes Smac mimetic compound 3-induced extrinsic apoptosis pathway and results in synergistic cancer cell death. Apoptosis 2011;16:45-54.
12. Khong T, Spencer A. Targeting heat shock protein 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. Mol Cancer Ther 2011;10:1909-17.
13. Beck R, Dejeans N, Glorieux C, Pedrosa RC, Vasquez D, Valderrama JA, et al. Molecular chaperone Hsp90 as a target for oxidant-based anticancer therapies. Curr Med Chem 2011;18:2816-25.
14. Beck R, Pedrosa RC, Dejeans N, Glorieux C, Leveque P, Gallez B, et al. Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study. Invest New Drugs 2011;29:891-900.
15. Hagn F, Lagleder S, Retzlaff M, Rohrberg J, Demmer O, Richter K, et al. Structural analysis of the interaction between Hsp90 and the tumor suppressor protein. Nat Struct Mol Biol 2011;53.
16. Mehta PP, Whalen P, Baxi SM, Kung PP, Yamazaki S, Yin MJ. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90. Clin Cancer Res 2011;17:5432-42.
17. Breinig M, Mayer P, Harjung A, Goeppert B, Malz M, Penzel R, et al. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors. Clin Cancer Res 2011;17:2237-49.
18. Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 2011;17:1561-70.
19. Stellas D, El Hamidieh A, Patsavoudi E. Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol 2010;11:51.
20. Li D, Marchenko ND, Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 2011;18:1904-13.
21. Yu W, Wang J, Jin J, Qian W, Qian J, Cheng Y, et al. Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor. Leuk Res 2011;35:1212-8.
22. Wang G, Ye Y, Yang X, Liao H, Zhao C, Liang S. Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma. PLoS ONE 2011;6:e14573.
23. Meng Q, Chen X, Sun L, Zhao C, Sui G, Cai L. Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90. Mol Cell Biochem 2011;348:165-71.
24. Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J Biomed Biotechnol 2011;2011:875824.
25. Luo XG, Zou JN, Wang SZ, Zhang TC, Xi T. Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells. IUBMB Life 2010;62:194-9.
26. Ruden DM, Xiao L, Garfinkel MD, Lu X. Hsp90 and environmental impacts on epigenetic states: a model for the trans-generational effects of diethylstilbesterol (DES) on uterine development and cancer. Hum Mol Genet 2005;14:R147-55.
27. Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV, et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev 2011;25:1628-40.
28. Yan W, Zhang W, Jiang T. Oncogene addiction in gliomas: implications for molecular targeted therapy. J Exp Clin Cancer Res 2011;30:58.
29. Folkman J, Ryeom S. Is oncogene addiction angiogenesis-dependent. Cold Spring Harb Symp Quant Biol 2005;70:389-97.
30. Jonkers J, Berns A. Oncogene addiction: sometimes a temporary slavery. Cancer Cell 2004;6:535-8. (Pubitemid 40017696)
31. Workman P. Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction. Expert Rev Anticancer Ther 2002;2:611-4. (Pubitemid 35469482)
32. Tan SS, Ahmad I, Bennett HL, Singh L, Nixon C, Seywright M, et al. GRP78 upregulation is associated with androgen receptor status Hsp70-Hsp90 client proteins and castrate-resistant prostate cancer. J Pathol 2010;223:81-7.
33. Beck R, Verrax J, Gonze T, Zappone M, Pedrosa RC, Taper H, et al. Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death. Biochem Pharmacol 2009;77:375-83.
34. Kim HL, Cassone M, Otvos L, Vogiatzi Jr P. HIF-1alpha and STAT3 client proteins interacting with the cancer chaperone Hsp90: therapeutic considerations. Cancer Biol Ther 2008;7:10-4. (Pubitemid 351590444)
35. Shames DS, Minna JD. IP6K2 is a client for HSP90 and a target for cancer therapeutics development. Proc Natl Acad Sci USA 2008;105:1389-90. (Pubitemid 351346523)
36. Krukenberg KA, Southworth DR, Street TO, Agard DA. pH-dependent conformational changes in bacterial Hsp90 reveal a Grp94-like conformation at pH 6 that is highly active in suppression of citrate synthase aggregation. J Mol Biol 2009;390:278-91.
37. Crawford LJ, Walker B, Irvine AE. Proteasome inhibitors in cancer therapy. J Cell Commun Signal 2011;5:101-10.
38. Singh P, Godbole M, Rao G, Annarao S, Mitra K, Roy R, et al. Inhibition of autophagy stimulate molecular iodine-induced apoptosis in hormone independent breast tumors. Biochem Biophys Res Commun 2011;415:181-6.
39. Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, et al. Dual inhibition of tumor energy pathway by 2-deoxy glucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther 2011 [epub ahead of print].
40. Yao F, Wang G, Wei W, Tu Y, Tong H, Sun S. An autophagy inhibitor enhances the inhibition of cell proliferation. Mol Med Rep 2012;5:84-8
41. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006;107:1092-100. (Pubitemid 43156310)
42. Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, et al. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011;17:5132-9.
43. Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S, et al. A phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs 2010 [epub ahead of print].
44. Senju M, Sueoka N, Sato A, Iwanaga K, Sakao Y, Tomimitsu S, et al. Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines. J Cancer Res Clin Oncol 2006;132:150-8. (Pubitemid 43015775)
45. Schwock J, Pham NA, Cao MP, Hedley DW. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo. Cancer Chemother Pharmacol 2008;61:669-81.
46. Williams CR, Tabios R, Linehan WM, Neckers L. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. J Urol 2007;178:1528-32. (Pubitemid 47376711)
47. Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS, et al. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 2008;14:8302-7.
48. Day JE, Sharp SY, Rowlands MG, Aherne W, Lewis W, Roe SM, et al. Inhibition of Hsp90 with resorcylic acid macrolactones: synthesis and binding studies. Chemistry 2010;16:10366-72.
49. Donnelly A, Blagg BS. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem 2008;15:2702-17.
50. Sgobba M, Forestiero R, Degliesposti G, Rastelli G. Exploring the binding site of C-terminal hsp90 inhibitors. J Chem Inf Model 2010;50:1522-8.
51. Provencio M, Sanchez A, Garrido P, Valcarcel F. New molecular targeted therapies integrated with radiation therapy in lung cancer. Clin Lung Cancer 2010;11:91-7.
52. Lassi K, Dawson NA. Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives. Future Oncol 2011;7:551-8.
53. Merkel TJ, DeSimone JM. Dodging drug-resistant cancer with diamonds. Sci Transl Med 2011;3:73ps8.
54. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011;8:12-23.
55. Zaugg K, Yao Y, Reilly PT, Kannan K, Kiarash R, Mason J, et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev 2011;25:1041-51.
56. Kawai M, Furuta Y, Yahara K, Tsuru T, Oshima K, Handa N, et al. Evolution in an oncogenic bacterial species with extreme genome plasticity: Helicobacter pylori East Asian genomes. BMC Microbiol 2011;11:104.
57. Smith DG, Magwere T, Burchill SA. Oxidative stress and therapeutic opportunities: focus on the Ewing's sarcoma family of tumors. Expert Rev Anticancer Ther 2011;11:229-49.
58. Chen CH, Chang YJ, Ku MS, Chung KT, Yang JT. Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation. J Mol Med (Berl) 2011;89:303-15.
59. De Luca A, Moroni N, Serafino A, Primavera A, Pastore A, Pedersen JZ, et al. Treatment of doxorubicin resistant MCF7/Dx cells with nitric oxide causes histone glutathionylation and reversal of drug resistance. Biochem J 2011;440:175-83.
60. de Almagro MC, Selga E, Thibaut R, Porte C, Noe V, Ciudad CJ. UDP-glucuronosyltransferase 1A6 overexpression in breast cancer cells resistant to methotrexate. Biochem Pharmacol 2011;81:60-70.
61. Prodromou C. The 'active life' of Hsp90 complexes. Biochim Biophys Acta 2011 [epub ahead of print].
62. Zhang H, Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 2004;82:488-99. (Pubitemid 39149859)
63. Shipp C, Watson K, Jones GL. Associations of HSP90 client proteins in human breast cancer. Anticancer Res 2011;31:2095-101.
64. Tan SS, Ahmad I, Bennett HL, Singh L, Nixon C, Seywright M, et al. GRP78 upregulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant prostate cancer. J Pathol 2011;223:81-7.
65. Truman AW, Millson SH, Nuttall JM, Mollapour M, Prodromou C, Piper PW. In the yeast heat shock response, Hsf1-directed induction of Hsp90 facilitates the activation of the Slt2 (Mpk1) mitogen-activated protein kinase required for cell integrity. Eukaryot Cell 2007;6:744-52. (Pubitemid 46697554)
66. Becker B, Multhoff G, Farkas B, Wild PJ, Landthaler M, Stolz W, et al. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp Dermatol 2004;13:27-32. (Pubitemid 38165435)
67. Galea-Lauri J, Richardson AJ, Latchman DS, Katz DR. Increased heat shock protein 90 (hsp90) expression leads to increased apoptosis in the monoblastoid cell line U937 following induction with TNF-alpha and cycloheximide: a possible role in immunopathology. J Immunol 1996;157:4109-18. (Pubitemid 126449323)
68. Kawagoe J, Abe K, Aoki M, Kogure K. Induction of HSP90 alpha heat shock mRNA after transient global ischemia in gerbil hippocampus. Brain Res 1993;621:121-5. (Pubitemid 23242169)
69. Jarosz DF, Lindquist S. Hsp90 and environmental stress transform the adaptive value of natural genetic variation. Science 2010;330:1820-4.
70. Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 2005;309:2185-9. (Pubitemid 41396062)
71. Queitsch C, Sangster TA, Lindquist S. Hsp90 as a capacitor of phenotypic variation. Nature 2002;417:618-24. (Pubitemid 34614814)
72. Rutherford SL, Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature 1998;396:336-42. (Pubitemid 28557387)
73. Sollars V, Lu X, Xiao L, Wang X, Garfinkel MD, Ruden DM. Evidence for an epigenetic mechanism by which Hsp90 acts as a capacitor for morphological evolution. Nat Genet 2003;33:70-4. (Pubitemid 36068685)
74. Ruden DM. Identification of Schizosaccharomyces pombe transcription factor PGA4, which binds cooperatively to Saccharomyces cerevisiae GAL4-binding sites. Mol Cell Biol 1990;10:1432-8.
75. Ruden DM, Garfinkel MD, Sollars VE, Lu X. Waddington's widget: Hsp90 and the inheritance of acquired characters. Semin Cell Dev Biol 2003;14:301-10. (Pubitemid 38160955)
76. Ruden DM, Garfinkel MD, Xiao L, Lu X. Epigenetic regulation of trinucleotide repeat expansions and contractions and the biased embryos hypothesis for rapid morphological evolution. Curr Genomics 2005;6:145-55. (Pubitemid 40753861)
77. Ruden DM, Jamison DC, Zeeberg BR, Garfinkel MD, Weinstein JN, Rasouli P, et al. The EDGE hypothesis: epigenetically directed genetic errors in repeat-containing proteins (RCPs) involved in evolution, neuroendocrine signaling, and cancer. Front Neuroendocrinol 2008;29:428-44.
78. Gangaraju VK, Yin H, Weiner MM, Wang J, Huang XA, Lin H. Drosophila Piwi functions in Hsp90-mediated suppression of phenotypic variation. Nat Genet 2011;43:153-8.
79. Xiao L, Lu X, Ruden DM. Effectiveness of hsp90 inhibitors as anti-cancer drugs. Mini Rev Med Chem 2006;6:1137-43. (Pubitemid 44524456)
80. Xiao L, Rasouli P, Ruden DM. Possible effects of early treatments of hsp90 inhibitors on preventing the evolution of drug resistance to other anti-cancer drugs. Curr Med Chem 2007;14:223-32. (Pubitemid 46043917)
81. Andre N, Meille C. Taxanes in paediatric oncology: and now? Cancer Treat Rev 2006;32:65-73. (Pubitemid 43362228)
82. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003;63:2139-44. (Pubitemid 36538618)
83. Nguyen DM, Lorang D, Chen GA, Stewart JHt, Tabibi E, Schrump DS. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann Thorac Surg 2001;72:371-8 [discussion 8-9].
84. Nguyen DM, Chen A, Mixon A, Schrump DS. Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin. J Thorac Cardiovasc Surg 1999;118:908-15. (Pubitemid 29511075)
85. Munster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res 2001;7:2228-36.
86. See: Sausville EA. Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 7; 2001:2155-58.
87. Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, et al. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 2001;15:1537-43. (Pubitemid 32994672)
88. Srethapakdi M, Liu F, Tavorath R, Rosen N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res 2000;60:3940-6. (Pubitemid 32204590)
89. Peyrone M. Ueber die Einwirkung des Ammoniaks auf Platinchlorür. Justus Liebigs Ann Chem 1844;51:1-29.
90. Sorenson CM, Eastman A. Mechanism of cis-diamminedichloroplatinum(II)- induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 1988;48:4484-8.
91. Frankenberg-Schwager M, Kirchermeier D, Greif G, Baer K, Becker M, Frankenberg D. Cisplatin-mediated DNA double-strand breaks in replicating but not in quiescent cells of the yeast Saccharomyces cerevisiae. Toxicology 2005;212:175-84. (Pubitemid 40981974)
92. Vasilevskaya IA, Rakitina TV, O'Dwyer PJ. Quantitative effects on c-Jun Nterminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines. Mol Pharmacol 2004;65:235-43. (Pubitemid 38113905)
93. Vasilevskaya IA, Rakitina TV, O'Dwyer PJ. Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction. Cancer Res 2003;63:3241-6. (Pubitemid 36735878)
94. Liao ZY, Zhang SH, Zhen YS. Synergistic effects of geldanamycin and antitumor drugs. Yao Xue Xue Bao 2001;36:569-75.
95. Fedier A, Stuedli A, Fink D. Presence of MLH1 protein aggravates the potential of the HSP90 inhibitor radicicol to sensitize tumor cells to cisplatin. Int J Oncol 2005;27:1697-705.
96. Bagatell R, Beliakoff J, David CL, Marron MT, Whitesell L. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int J Cancer 2005;113:179-88. (Pubitemid 39628307)
97. Sano M. Radicicol and geldanamycin prevent neurotoxic effects of anticancer drugs on cultured embryonic sensory neurons. Neuropharmacology 2001;40:947-53. (Pubitemid 32510808)
98. Mitsiades CS, Mitsiades N, Richardson PG, Treon SP, Anderson KC. Novel biologically based therapies for Waldenstrom's macroglobulinemia. Semin Oncol 2003;30:309-12. (Pubitemid 36506332)
99. Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, Bisht KS, et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 2004;3:551-66. (Pubitemid 39193734)
100. Wajant H, Gerspach J, Pfizenmaier K. Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev 2005;16:55-76. (Pubitemid 40279117)
101. Siegelin MD, Habel A, Gaiser T. 17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis. Neurobiol Dis 2009;33:243-9.
102. Wang X, Ju W, Renouard J, Aden J, Belinsky SA, Lin Y. 17-Allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway. Cancer Res 2006;66:1089-95. (Pubitemid 43165977)
103. Vasilevskaya IA, O'Dwyer PJ. 17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines. Biochem Pharmacol 2005;70:580-9. (Pubitemid 40978548)
104. Ma Y, Lakshmikanthan V, Lewis RW, Kumar MV. Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin. Mol Cancer Ther 2006;5:170-8.
105. Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy- geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 2006;12:584-90. (Pubitemid 43166153)
106. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002;94:504-13. (Pubitemid 34411289)
107. Chen L, Meng S, Wang H, Bali P, Bai W, Li B, et al. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 2005;4:1311-9.
108. Boyle GM, Martyn AC, Parsons PG. Histone deacetylase inhibitors and malignant melanoma. Pigment Cell Res 2005;18:160-6. (Pubitemid 40733334)
109. Gore SD, Carducci MA. Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin Investig Drugs 2000;9:2923-34.
110. Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999;18:7016-25. (Pubitemid 30028872)
111. Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P, et al. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 2003;63:8420-7. (Pubitemid 37549498)
112. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005;105:1768-76. (Pubitemid 40223701)
113. Yao Q, Nishiuchi R, Li Q, Kumar AR, Hudson WA, Kersey JH. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin Cancer Res 2003;9:4483-93. (Pubitemid 37248407)
114. George P, Bali P, Cohen P, Tao J, Guo F, Sigua C, et al. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res 2004;64:3645-52. (Pubitemid 38657944)
115. Radujkovic A, Schad M, Topaly J, Veldwijk MR, Laufs S, Schultheis BS, et al. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL-inhibition of P-glycoprotein function by 17-AAG. Leukemia 2005;19:1198-206. (Pubitemid 40946004)
116. Zsebik B, Citri A, Isola J, Yarden Y, Szollosi J, Vereb G. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett 2006;104:146-55. (Pubitemid 43330721)
117. Premkumar DR, Arnold B, Jane EP, Pollack IF. Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells. Mol Carcinog 2006;45:47-59. (Pubitemid 43122369)
118. Jia W, Yu C, Rahmani M, Krystal G, Sausville EA, Dent P, et al. Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood 2003;102:1824-32. (Pubitemid 37022579)
119. Pelicano H, Carew JS, McQueen TJ, Andreeff M, Plunkett W, Keating MJ, et al. Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia 2006;20:610-9.
120. Mesa RA, Loegering D, Powell HL, Flatten K, Arlander SJ, Dai NT, et al. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 2005;106:318-27. (Pubitemid 40967208)
121. Barker CR, McNamara AV, Rackstraw SA, Nelson DE, White MR, Watson AJ, et al. Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage. Nucleic Acids Res 2006;34:1148-57.
122. Zaarur N, Gabai VL, Porco JA, Calderwood Jr S, Sherman MY. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. Cancer Res 2006;66:1783-91. (Pubitemid 43259964)
123. Harashima K, Akimoto T, Nonaka T, Tsuzuki K, Mitsuhashi N, Nakano T. Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor. Int J Radiat Biol 2005;81:63-76. (Pubitemid 40674534)
124. Enmon R, Yang WH, Ballangrud AM, Solit DB, Heller G, Rosen N, et al. Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer Res 2003;63:8393-9. (Pubitemid 37549494)
125. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, et al. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 2003;63:8984-95. (Pubitemid 38064080)
126. Schabel Jr FM. Utility of drug-resistant organisms in cancer chemotherapy studies. Ann N Y Acad Sci 1958;76:442-53 [discussion 53-6].
127. Wider D, Peli-Gulli MP, Briand PA, Tatu U, Picard D. The complementation of yeast with human or Plasmodium falciparum Hsp90 confers differential inhibitor sensitivities. Mol Biochem Parasitol 2009;164:147-52.
128. Abbas-Terki T, Donze O, Briand PA, Picard D. Hsp104 interacts with Hsp90 cochaperones in respiring yeast. Mol Cell Biol 2001;21:7569-75. (Pubitemid 32988768)
129. Louvion JF, Abbas-Terki T, Picard D. Hsp90 is required for pheromone signaling in yeast. Mol Biol Cell 1998;9:3071-83. (Pubitemid 28516622)
130. Rodriguez-Caban J, Gonzalez-Velazquez W, Perez-Sanchez L, Gonzalez-Mendez R, Valle NR. Calcium/calmodulin kinase1 and its relation to thermotolerance and HSP90 in Sporothrix schenckii: an RNAi and yeast two-hybrid study. BMC Microbiol 2011;11:162.
131. Singh SD, Robbins N, Zaas AK, Schell WA, Perfect JR, Cowen LE. Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog 2009;5:e1000532.
132. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, et al. Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol 2010;176:2092-7.
133. Li S. The possible cellular mechanism for extending lifespan of mice with rapamycin. Biol Proced Online 2009;11:1-2.
134. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009;460:392-5.
135. Harrison B, Tran TT, Taylor D, Lee SD, Min KJ. Effect of rapamycin on lifespan in Drosophila. Geriatr Gerontol Int 2010;10:110-2.
136. Athar M, Kopelovich L. Rapamycin and mTORC1 inhibition in the mouse: skin cancer prevention. Cancer Prev Res (Phila) 2011;4:957-61.
137. Gruppuso PA, Boylan JM, Sanders JA. The physiology and pathophysiology of rapamycin resistance: implications for cancer. Cell Cycle 2011;10:1050-8.
138. Macaskill EJ, Bartlett JM, Sabine VS, Faratian D, Renshaw L, White S, et al. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study. Breast Cancer Res Treat 2011;128:725-34.
139. Wong SW, Tiong KH, Kong WY, Yue YC, Chua CH, Lim JY, et al. Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through upregulation of p73. Breast Cancer Res Treat 2011;128:301-13.
140. Leidel S, Pedrioli PG, Bucher T, Brost R, Costanzo M, Schmidt A, et al. Ubiquitin-related modifier Urm1 acts as a sulphur carrier in thiolation of eukaryotic transfer RNA. Nature 2009;458:228-32.
141. Ramanathan A, Schreiber SL. Multilevel regulation of growth rate in yeast revealed using systems biology. J Biol 2007;6:3.
142. Cole DR, Beckloff GL, Rousselot LM. Clinical results with hydroxyurea in cancer chemotherapy; preliminary report. N Y State J Med 1965;65:2132-6.
143. Fishbein WN, Carbone PP, Freireich EJ, Misra D, Frei 3rd E. Clinical trials of hydroxyurea in patients with cancer and leukemia. Clin Pharmacol Ther 1964;5:574-80.
144. Sears ME. Phase II studies of hydroxyurea (Nsc-32065) in adults: cancer of the breast. Cancer Chemother Rep 1964;40:43.
145. Origenes ML, Beatty Jr EC, Brubaker Jr C, Hammond D, Hartmann JR, Shore N, et al. Trial of hydroxyurea (Nsc-32065) in cancer in children. Cancer Chemother Rep 1964;37:41-6.
146. Kao J, Genden EM, Gupta V, Policarpio EL, Burri RJ, Rivera M, et al. Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer. Cancer 2011;117:318-26.
147. Hoglund L, Pontis E, Reichard P. Deoxyribonucleotide metabolism in hydroxyurea-resistant V79 hamster cells. Eur J Biochem 1991;196:239-45.
148. Young CW, Schochetman G, Karnofsky DA. Hydroxyurea-induced inhibition of deoxyribonucleotide synthesis: studies in intact cells. Cancer Res 1967;27:526-34.
149. Kozhina TN, Kozhin SA, Korolev VG. Gene RAD31 is identical to gene MEC1 of yeast Saccharomyces cerevisiae. Genetika 2011;47:610-4.
150. Donnianni RA, Ferrari M, Lazzaro F, Clerici M, Tamilselvan Nachimuthu B, Plevani P, et al. Elevated levels of the polo kinase Cdc5 override the Mec1/ATR checkpoint in budding yeast by acting at different steps of the signaling pathway. PLoS Genet 2010;6:e1000763.
151. Carballo JA, Cha RS. Meiotic roles of Mec1, a budding yeast homolog of mammalian ATR/ATM. Chromosome Res 2007;15:539-50. (Pubitemid 47221372)
152. Morrow DM, Tagle DA, Shiloh Y, Collins FS, Hieter P. TEL1, an S. cerevisiae homolog of the human gene mutated in ataxia telangiectasia, is functionally related to the yeast checkpoint gene MEC1. Cell 1995;82:831-40.
153. Lee J, Kannagi M, Ferrante RJ, Kowall NW, Ryu H. Activation of Ets-2 by oxidative stress induces Bcl-xL expression and accounts for glial survival in amyotrophic lateral sclerosis. FASEB J 2009;23:1739-49.
154. Katada H, Nishikawa K, Yoneda T, Kitamura H, Nakajima A, Mikami R. Role of immune skin reactions in progressive lung cancer during the administration of OK-432-relation to reactions to DNCB, PPD and Su-PS. Gan To Kagaku Ryoho
155. Munzarova M, Kovarik J, Hlavkova J, Popelinsky L, Lauerova L. DNCB and PPD skin tests and prognosis in 152 patients with breast cancer. A prospective 2-year follow-up. Neoplasma 1985;32:45-50. (Pubitemid 15076254)
156. Munzarova M, Kovarik J, Ninger E, Zemanova D, Lauerova L, Kolcova V, et al. DNCB and PPD skin testing in breast cancer. Neoplasma 1983;30:385-9.
157. Cunningham TJ, Daut D, Wolfgang PE, Mellyn M, Maciolek S, Sponzo RW, et al. A correlation of DNCB-induced delayed cutaneous hypersensitivity reactions and the course of disease in patients with recurrent breast cancer. Cancer 1976;37:1696-700.
158. Sadoff L, Glovsky M, Alenty A, Catalona WJ, Taylor PT, Chretien PB. DNCB test in cancer patients. N Engl J Med 1972;287:47-8.
159. Yamashita T, Nakamaru-Ogiso E, Miyoshi H, Matsuno-Yagi A, Yagi T. Roles of bound quinone in the single subunit NADH-quinone oxidoreductase (Ndi1) from Saccharomyces cerevisiae. J Biol Chem 2007;282:6012-20. (Pubitemid 47100858)
160. Seo BB, Wang J, Flotte TR, Yagi T, Matsuno-Yagi A. Use of the NADH-quinone oxidoreductase (NDI1) gene of Saccharomyces cerevisiae as a possible cure for complex I defects in human cells. J Biol Chem 2000;275:37774-8. (Pubitemid 32004893)
161. Seo BB, Matsuno-Yagi A, Yagi T. Modulation of oxidative phosphorylation of human kidney 293 cells by transfection with the internal rotenone-insensitive NADH-quinone oxidoreductase (NDI1) gene of Saccharomyces cerevisiae. Biochim Biophys Acta 1999;1412:56-65. (Pubitemid 29238117)
162. Lee R, Britz-McKibbin P. Differential rates of glutathione oxidation for assessment of cellular redox status and antioxidant capacity by capillary electrophoresis-mass spectrometry: an elusive biomarker of oxidative stress. Anal Chem 2009;81:7047-56.
163. Xu S, He Y, Vokurkova M, Touyz RM. Endothelial cells negatively modulate reactive oxygen species generation in vascular smooth muscle cells: role of thioredoxin. Hypertension 2009;54:427-33.
164. Raftos JE, Dwarte TM, Luty A, Willcock CJ. Direct measurement of the rate of glutathione synthesis in 1-chloro-2,4-dinitrobenzene treated human erythrocytes. Redox Rep 2006;11:9-14. (Pubitemid 44111118)
165. Tanaka T, Nakamura H, Yodoi J, Bloom ET. Redox regulation of the signaling pathways leading to eNOS phosphorylation. Free Radic Biol Med 2005;38:1231-42. (Pubitemid 40445540)
166. Fujise H, Higa K, Kanemaru T, Fukuda M, Adragna NC, Lauf PK. GSH depletion, K-Cl cotransport, and regulatory volume decrease in high-K/high-GSH dog red blood cells. Am J Physiol Cell Physiol 2001;281:C2003-9.
167. 2+ signaling in endothelial cells. Am J Physiol 1995;268:H278-87.
168. Den Boer PJ, van Loon AA, Mackenbach P, van der Schans GP, Grootegoed JA. Effect of glutathione depletion on the cytotoxicity of xenobiotics and induction of single-strand DNA breaks by ionizing radiation in isolated hamster round spermatids. J Reprod Fertil 1990;88:259-69. (Pubitemid 20054560)
169. Mkoji GM, Smith JM, Prichard RK. Glutathione redox state, lipid peroxide levels, and activities of glutathione enzymes in oltipraz-treated adult Schistosoma mansoni. Biochem Pharmacol 1989;38:4307-13. (Pubitemid 20009031)
170. Harlan JM, Levine JD, Callahan KS, Schwartz BR, Harker LA. Glutathione redox cycle protects cultured endothelial cells against lysis by extracellularly generated hydrogen peroxide. J Clin Invest 1984;73:706-13. (Pubitemid 14156852)
171. Sanz A, Soikkeli M, Portero-Otin M, Wilson A, Kemppainen E, McIlroy G, et al. Expression of the yeast NADH dehydrogenase Ndi1 in Drosophila confers increased lifespan independently of dietary restriction. Proc Natl Acad Sci USA 2010;107:9105-10.
172. Hekimi S, Lapointe J, Wen Y. Taking a good look at free radicals in the aging process. Trends Cell Biol 2011;21:569-76.
173. Rutherford SL, Carpenter AT. The effect of sequence homozygosity on the frequency of X-chromosomal exchange in Drosophila melanogaster females. Genetics 1988;120:725-32. (Pubitemid 18260508)
174. Rutherford SL, Henikoff S. Quantitative epigenetics. Nat Genet 2003;33:6-8. (Pubitemid 36068670)
175. Hubbard J, Erlichman C, Toft DO, Qin R, Stensgard BA, Felten S, et al. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Invest New Drugs 2011;29:473-80.
176. Ohba S, Hirose Y, Yoshida K, Yazaki T, Kawase T. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells. J Neurosurg 2010;112:33-42.
177. Oikonomou E, Koc M, Sourkova V, Andera L, Pintzas A. Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. PLoS ONE 2011;6:e21632.
178. Takahashi S. Combination therapy with arsenic trioxide for hematological malignancies. Anticancer Agents Med Chem 2010;10:504-10.
179. Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003;63:5126-35. (Pubitemid 37022654)
180. Gilbert JA, Adhikari LJ, Lloyd RV, Rubin J, Haluska P, Carboni JM, et al. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocr Relat Cancer 2010;17:623-36.
181. Yao Q, Nishiuchi R, Kitamura T, Kersey JH. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway. Leukemia 2005;19:1605-12. (Pubitemid 43090405)
182. Reka AK, Kuick R, Kurapati H, Standiford TJ, Omenn GS, Keshamouni VG. Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach. J Thorac Oncol 2011;6:1784-92.
183. Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO, Karnitz LM. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 2003;278:52572-7. (Pubitemid 38035854)
184. Yao Q, Weigel B, Kersey J. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. Clin Cancer Res 2007;13:1591-600. (Pubitemid 46450452)
185. Nguyen A, Su L, Campbell B, Poulin NM, Nielsen TO. Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma. Sarcoma 2009;2009:794901.
186. Al Shaer L, Walsby E, Gilkes A, Tonks A, Walsh V, Mills K, et al. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. Br J Haematol 2008;141:483-93. (Pubitemid 351550553)
187. Huang HC, Yang Y, Nanda A, Koria P, Rege K. Synergistic administration of photothermal therapy and chemotherapy to cancer cells using polypeptide-based degradable plasmonic matrices. Nanomedicine 2011;6:459-73.
188. Widakowich C, Dinh P, de Azambuja E, Awada A, Piccart-Gebhart M. HER-2 positive breast cancer: what else beyond trastuzumab-based therapy. Anticancer Agents Med Chem 2008;8:488-96.